The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
SYNIMMUNE GmbH
Tübingen, Germany
A
1-10 Employees
-
Key takeaway
SYNIMMUNE GmbH is focused on developing innovative bispecific anti-tumor antibodies, particularly for treating orphan hematopoietic malignancies.
Highlighted product
Product
SYNIMMUNE GmbH: Bispecific antibodies
Harbour Biomed
Shanghai, China
D
51-100 Employees
2016
Key takeaway
Harbour BioMed is dedicated to the development of novel antibody therapeutics, including bispecific antibodies that leverage their HCAb platform to create immune cell engagers capable of more effective tumor targeting. Their innovative approach aims to enhance treatment potency and safety, particularly in immunology and oncology.
Highlighted product
Product
Bispecific Antibodies-hbm holdings
Abzyme Therapeutics
Royersford, United States
B
11-50 Employees
2010
Key takeaway
Abzyme is actively seeking strategic collaborations to enhance antibody development, highlighting its capability to create a wide range of bispecific products through its innovative single-domain antibody generation platform.
Highlighted product
Product
Abz2 bispecific platform
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Velabs Therapeutics
Heidelberg, Germany
A
11-50 Employees
2017
Key takeaway
VERAXA Biotech specializes in the development of bispecific antibody constructs, integrating advanced solutions for targeted antibody discovery and bioconjugation. Their expertise is backed by a team with extensive experience in life sciences and technology.
Highlighted product
Product
Bispecific Antibody Constructs | VERAXA
Abpro
Woburn, United States
B
11-50 Employees
2007
Key takeaway
Abpro Corporation is developing a pipeline of T-cell engagers utilizing a tetravalent bispecific (TetraBi) format, which enhances efficacy and safety by optimizing antibody product formats. This innovative approach positions Abpro at the forefront of next-generation antibody therapies.
Highlighted product
Product
Technology – Abpro Corporation
NovImmune
Plan-les-Ouates, Switzerland
A
101-250 Employees
1998
Key takeaway
The company is now focusing on its bispecific technology to develop a pipeline of multispecific antibodies, emphasizing safe and selective blockade of CD47 on tumors. This aligns with their commitment to advancing bispecific antibody development.
Highlighted product
Core business
Light Chain Bioscience – A brand of Novimmune SA
CiMaas
Maastricht, Netherlands
A
1-10 Employees
2015
Key takeaway
CiMaas is focused on developing therapies that engage the immune system to improve cancer treatment, particularly for patients who do not respond to standard care. Their approach highlights the importance of using multiple components of the immune system, which aligns with the concept of bispecific antibodies that can target multiple antigens simultaneously.
Highlighted product
Product
BiSpecific engager - Cimaas
Kymab
Cambridge, United Kingdom
A
101-250 Employees
2010
Key takeaway
Kymab, a Sanofi company based in Cambridge, UK, is focused on developing novel human antibody-based therapies, including bispecific antibodies, which are designed to be smarter and more effective medicines. Their unique platforms generate a wide range of fully-human antibodies, enhancing opportunities in therapeutic antibody and vaccine development.
Highlighted product
Product
Bispecific antibodies
Xencor
Monrovia, United States
B
51-100 Employees
1997
Key takeaway
Xencor specializes in the development of bispecific antibodies through its innovative XmAb technology, which allows for the rapid creation of differentiated antibody drug candidates by modifying Fc domains. This approach enhances the efficacy and half-life of antibodies, making Xencor a key player in advancing bispecific antibody therapies.
Highlighted product
Product
Bispecific Fc Domains | Xencor
LiliumX
United Kingdom
A
1-10 Employees
2021
Key takeaway
The company specializes in treating solid tumors using bispecific antibody-drug conjugates, highlighting their innovative approach to drug design and discovery in this area.
Highlighted product
Core business
Home
Technologies which have been searched by others and may be interesting for you:
A bispecific antibody is a type of engineered protein that can simultaneously bind to two different antigens or epitopes. This functionality allows bispecific antibodies to engage multiple targets, which can enhance therapeutic efficacy in various diseases, particularly in cancer treatment. By bridging two distinct cells, such as immune cells and cancer cells, these antibodies facilitate a more efficient immune response against tumors. Their unique design makes them a valuable tool in targeted therapies, offering potential advantages over traditional monoclonal antibodies.
Bispecific antibodies are engineered proteins that can simultaneously bind to two different antigens or epitopes. This unique capability allows them to bring together immune cells and target cells, enhancing the immune response against diseases such as cancer. By bridging the gap between T cells and tumor cells, bispecific antibodies can activate T cells to attack and destroy the cancer cells more effectively. The structure of bispecific antibodies enables them to recognize and engage multiple targets, which can help overcome resistance mechanisms that tumors might develop against traditional monoclonal antibodies. Their dual-binding properties make them valuable tools in immunotherapy, offering the potential for more precise and effective treatment options.
Bispecific antibodies have gained prominence in the field of medicine due to their unique ability to simultaneously bind two different antigens. This characteristic enables them to be utilized in various therapeutic applications, particularly in oncology. For instance, bispecific antibodies can redirect immune cells to target and destroy cancer cells more effectively, enhancing the immune response against tumors. In addition to cancer treatment, bispecific antibodies are also being explored for use in autoimmune diseases and infectious diseases. By targeting specific pathways or cells involved in these conditions, they can potentially modulate immune responses, offering innovative treatment options. Their versatility in targeting multiple pathways or cells makes them a valuable tool in advancing personalized medicine.
Developing bispecific antibodies presents several challenges that researchers and manufacturers must address. One significant issue is the complexity of engineering these molecules, as they need to be designed to bind simultaneously to two different targets. This requires precise control over the antibody structure, which can lead to difficulties in maintaining stability and functionality. Another challenge is the potential for immunogenicity, where the immune system may recognize the bispecific antibody as foreign, leading to adverse reactions. Additionally, optimizing the pharmacokinetics of these antibodies can be problematic. Factors such as distribution, metabolism, and elimination must be finely tuned to ensure efficacy while minimizing side effects. Overall, the development process demands advanced technologies and methodologies to overcome these hurdles effectively.
Bispecific antibodies are engineered to simultaneously bind to two different antigens or epitopes, a significant departure from traditional monoclonal antibodies, which typically target a single antigen. This dual-targeting capability allows bispecific antibodies to engage multiple pathways or cells, enhancing therapeutic efficacy and specificity, particularly in oncology and immunotherapy. Moreover, bispecific antibodies can facilitate the recruitment of immune cells to tumor sites, thus promoting targeted destruction of cancer cells. Traditional monoclonal antibodies, while effective, often lack this multifaceted approach, which can limit their effectiveness against complex diseases that involve multiple cellular interactions. The unique design of bispecific antibodies opens up new avenues for treatment strategies that are not achievable with standard monoclonal antibodies.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | Germany |
| Amount of fitting manufacturers | 5653 |
| Amount of suitable service providers | 4408 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1997 |
| Youngest suiting company | 2021 |
20%
40%
60%
80%
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of Bispecific Antibody?
Start-Ups who are working in Bispecific Antibody are LiliumX
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Biotechnology, Other, Pharmaceuticals, Medical, IT, Software and Services
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
